- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02239393
Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study (MESCAMS)
MEsenchymal Stem Cell Therapy for CAnadian MS Patients
The mechanism of action of MSC relies on their ability to modulate pathogenic immune responses and provide neuroprotection through the release of anti-apoptotic, anti-oxidant and trophic factors as demonstrated by in-vitro and in-vivo preclinical studies.
Patients will be randomized to receive immediate vs. delayed treatment with either a dose equal to 1-2 millions/kg of body weight of autologous MSC, or equivalent volume of suspension media at baseline. At week 24 treatments will be reversed.
The primary outcome of this study is to evaluate:
- Treatment's safety within one year from MSC administration by measuring the number, time-frame and severity of adverse events and
- Treatment's activity in terms of reduction in total number of gadolinium-enhancing lesions (GEL) by magnetic resonance imaging (MRI) scans.
Secondary outcomes are to gain preliminary information on the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The mechanism of action of Mesenchymal Stem Cells (MSCs) relies on their ability to modulate pathogenic immune responses and provide neuroprotection through the release of anti-apoptotic, anti-oxidant and trophic factors as demonstrated by in vitro and in vivo preclinical studies.
Patients will be randomized to receive immediate vs. delayed treatment with either a dose equal to 1-2 millions/kg of body weight of autologous MSC, or equivalent volume of suspension media at baseline. At 6 months treatments will be reversed.
The primary outcome of this study is to evaluate
- treatment's safety within one year from MSC administration by measuring the the number, time-frame and severity of adverse event and
- treatment's activity in terms of reduction in the total number of contrast-gadolinium enhancing lesions (GEL) by magnetic resonance imaging (MRI) scans.
Secondary outcomes are to gain preliminary information on the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1R9
- Health Sciences Centre
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Ottawa Hospital - General Campus
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
1) Males and females with a diagnosis of MS
Relapsing remitting MS (RRMS) not responding to at least 1 year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, dimethyl fumarate, teriflunomide, alemtuzumab) as evidenced by at least one of the following:
- i) ≥1 clinically documented relapse in past 12 months
- ii) ≥2 clinically documented relapses in past 24 months
- iii) ≥1 gadolinium-enhancing lesion (GEL) at MRI performed within the past 12 months
Secondary progressive MS (SPMS) not responding to at least a year of attempted therapy with one or more of the approved therapies (beta-interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, dimethylfumarate, teriflunomide, alemtuzumab) as evidenced by both:
- i) an increase of ≥1 EDSS point (if at randomization EDSS ≤ 5.0) or 0.5 EDSS point (if at randomization EDSS ≥ 5.5) in the past 12 months
- ii) ≥1 clinically documented relapse or ≥ 1 gadolinium-enhancing lesion (GEL) at MRI within the past 12 months
Primary progressive MS (PPMS) patients with all the following features:
- i) an increase of ≥1 EDSS point (if at randomization EDSS ≤ 5.0) or 0.5 EDSS point (if at randomization EDSS ≥5.5), in the past 12 months
- ii) ≥ 1 gadolinium-enhancing lesion (GEL) at MRI performed within the past 12 months
- iii) positive cerebrospinal fluid (CSF) (oligoclonal banding)
- 2) Age 18 to 50 years old, inclusive at time of informed consent
- 3) Disease duration 2 to 15 years (inclusive)
- 4) EDSS 2.5 to 6.5
- 5) Able and willing to sign informed consent prior to any study-related activities
Exclusion Criteria:
- 1) RRMS not fulfilling inclusion criteria
- 2) SPMS not fulfilling inclusion criteria
- 3) PPMS not fulfilling inclusion criteria
- 4) A history of active or chronic infection including infection with HIV1-2, chronic Hepatitis B or Hepatitis C
- 5) Treatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the 3 months prior to randomization
- 6) Previous treatment with cladribine or alemtuzumab
- 7) Treatment with interferon-beta, glatiramer acetate, teriflunomide or dimethyl fumarate within the 30 days prior to randomization (all teriflunomide patients will be required to have followed a wash-out with either cholestyramine or activated charcoal as indicated in the product monograph)
- 8) Treatment with corticosteroids within the 30 days prior to randomization
- 9) Relapse occurred during the 60 days prior to randomization
- 10) Previous history of a malignancy (patient reported) other than basal cell carcinoma of the skin or carcinoma in situ that has been in remission for more than one year
- 11) Severely limited life expectancy by any other co-morbid illness
- 12) History of previous diagnosis of myelodysplasia or previous hematologic disease (patient reported) or current clinically relevant abnormalities of white blood cell counts
- 13) Pregnancy or risk of pregnancy (this includes participants that are not willing to practice active contraception for the duration of the study)
- 14) eGFR < 60 mL/min/1.73m2 or known renal failure or inability to undergo MRI examination
- 15) Known allergy to gentamicin or related aminoglycosides
- 16) Inability to give written informed consent in accordance with research ethics board guidelines
- 17) Concomitant participation in another clinical trial
- 18) Inability to adhere to protocol according to the investigator's medical judgement
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Autologous Mesenchymal Stem Cells
At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight.
At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
|
Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization. Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product). |
Expérimental: Suspension media
At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight.
At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
|
Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization. Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product). |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Safety
Délai: 24 weeks from first infusion
|
Incidence and severity of adverse events in MSC treatment group compared to placebo group
|
24 weeks from first infusion
|
Efficacy
Délai: 24 weeks from first infusion
|
Total number of gadolinium-enhancing lesions (GEL) on MRI scan
|
24 weeks from first infusion
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Efficacy
Délai: 48 weeks from first infusion
|
Number of gadolinium-enhancing lesions (GEL) counted over week 28, 36, 48 compared with the number of GEL counted over 4, 12, 24 weeks.
|
48 weeks from first infusion
|
Efficacy
Délai: 24 weeks from first infusion
|
Combined unique magnetic resonance imaging (MRI) activity (number of new or enlarging T2, or enhancing or re-enhancing lesions), volume of gadolinium-enhancing lesions (GEL) and volume of black holes (BH) over 4, 12, 24 weeks compared between treatment groups.
|
24 weeks from first infusion
|
Efficacy
Délai: 48 weeks from first infusion
|
Combined unique magnetic resonance imaging (MRI) activity, volume of gadolinium-enhancing lesions (GEL) and volume of black holes (BH) over week 28, 36, 48 compared with the same outcomes over 4, 12 and 24 weeks.
|
48 weeks from first infusion
|
Efficacy
Délai: 48 weeks from first infusion
|
Number of relapses in MSC treatment group vs. placebo group in the first 24 weeks and after cross-over re-treatment in the two groups.
|
48 weeks from first infusion
|
Efficacy
Délai: 48 weeks from first infusion
|
Time to sustained progression of disability and proportion of progression-free patients compared between treatment groups during the first 24 weeks and after cross-over.
|
48 weeks from first infusion
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Mark S. Freedman, MSc MD FRCPC, Ottawa Hospital Research Institute
Publications et liens utiles
Publications générales
- Thebault S, Reaume M, Marrie RA, Marriott JJ, Furlan R, Laroni A, Booth RA, Uccelli A, Freedman MS. High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Mult Scler Relat Disord. 2022 Mar;59:103535. doi: 10.1016/j.msard.2022.103535. Epub 2022 Jan 19.
- Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 20140368
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Mesenchymal Stem Cells
-
StemMedical A/SPas encore de recrutement
-
The University of Hong KongUniversity of CambridgeComplétéProblèmes éducatifsHong Kong
-
Oregon Research Behavioral Intervention Strategies...National Institute on Minority Health and Health Disparities (NIMHD)ComplétéDéveloppement du langageÉtats-Unis
-
Immunis, Inc.RecrutementAtrophie musculaireÉtats-Unis
-
Oregon Research Behavioral Intervention Strategies...Recrutement
-
Region SkaneLund University; Cambridge University Hospitals NHS Foundation Trust; University...Recrutement
-
Oxford ImmunotecComplétéTuberculoseÉtats-Unis, Afrique du Sud
-
Kessler FoundationRecrutement
-
DePuy InternationalRésiliéArthrose | La polyarthrite rhumatoïde | Nécrose vasculaire | Arthrite post-traumatique | Dysplasie congénitale de la hanche | Épiphyse fémorale capitale glissée | Troubles du collagène | Fractures fémorales traumatiques | Pseudarthrose des fractures fémoralesRoyaume-Uni
-
Xuzhou Medical UniversityRecrutement